BB-103

BB-103 (also known as BB-10010) is a recombinant human macrophage inflammatory protein-1 alpha (MIP-1α/CCL3) analog developed as a myeloprotective agent. The molecule features a single amino acid substitution (Asp26 to Ala) that prevents the aggregation characteristic of the wild-type protein, thereby improving its pharmacological profile and solubility. BB-103 acts as a potent inhibitor of hematopoietic stem cell (HSC) proliferation by temporarily arresting them in the G0 phase of the cell cycle. This mechanism is intended to protect the bone marrow from the cytotoxic effects of cycle-specific chemotherapy, potentially reducing the severity and duration of neutropenia. Clinical development reached Phase 1/2 trials for patients with advanced cancer receiving various chemotherapy regimens, but the program was ultimately discontinued.

Other names

recombinant human macrophage inflammatory protein-1 alpha analogMIP-1 alpha variantMIP1 alpha variantMIP 1 alpha variantAsp26-Ala MIP-1 alphaAsp-26-Ala MIP-1 alphaAsp 26-Ala MIP-1 alpha